Weight loss drugs: How a new wave of weight loss drugs is poised to change healthcare

Weight loss drugs: How a new wave of weight loss drugs is poised to change healthcare

From a $1 billion market in 2020 to a projected $100 billion market in 2030, novel weight loss drugs are all set to reshape healthcare. In this report, we will explore what’s driving this rapid growth and who the key players are. We will also have a look at the clinical trial space, detailing active trials across Phase I, II and III.

Please enter your contact details to proceed.

First Name*

Last Name*

Business Email*



By clicking download, you give consent to PreScouter to use the information you have provided to contact you about relevant content, products, and services.

We're committed to your privacy. You may unsubscribe from these communications at any time. For more information, check out our Privacy Policy.

Weight loss drugs: How a new wave of weight loss drugs is poised to change healthcare

Have you ever pondered the potential of a drug or pill to significantly alter the trajectory of global health, especially in the battle against obesity? The emergence of novel weight loss drugs is not just a fleeting trend; it’s an industry poised to revolutionize healthcare. 

From a market barely worth $1 billion in 2020, it’s on track to surge to a staggering $100 billion by 2030. This explosive growth raises an intriguing question: beyond shedding pounds, can these drugs reshape the overall healthcare sector? Find out more in our report!

Why are weight loss drugs dominating the healthcare industry?

Weight loss drugs are leading the way in healthcare due to their significant impact on obesity, a growing global concern. The report explores how the market’s expansion reflects the high demand and potential of these medications. Novo Nordisk leads the way, with their drug sales soaring, highlighting the effectiveness of their treatments.

The competition among pharmaceutical giants is intensifying, as they strive to capture a share of this lucrative market. This race underscores the importance of innovative solutions in addressing obesity. Hence, companies are investing heavily in research and development to create more effective drugs and weight loss supplements.

A shift in traditional weight loss methods:

Shift of traditional weight loss methods.

Moreover, these drugs offer more than just weight loss; they promise a reduction in obesity-related health issues. This dual benefit enhances their appeal, as they not only improve patients’ physical health but also reduce the economic burden associated with obesity and its related diseases on healthcare systems. Our report provides detailed insights into these significant developments which makes it a must-read for understanding the transformative role of weight loss medications.

Clinical trials for weight loss drugs on the rise:

Number of registered clinical trials

The weight-loss R&D sector is growing, moving beyond well-known industry players. This growth is driven by biotech firms progressing through early clinical trials and seeking partnerships to fast-track their projects. In 2023, the industry saw 30 new clinical trials, with 40% industry-sponsored. 

This activity is paralleled by a surge in scientific publications and patent filings on weight loss, with nearly 50,000 publications and around 90,000 patents in 2023, marking a significant increase of 33-40% from 2018. This highlights the sector’s dynamism and expanding focus on innovative weight management solutions.

The report emphasizes the importance of clinical trials for weight loss medications, showing their effectiveness and safety. These trials are key for drug approval and acceptance in the market. They provide concrete evidence of the benefits of these drugs in reducing obesity and related health issues.

Included in this report:

  • The growth forecast for the market of weight loss drugs.
  • Novo Nordisk’s semaglutide drugs’ success.
  • Major pharmaceuticals racing in the weight loss market.
  • Clinical trials focusing on GLP-1 based drugs.
  • Obesity in America, Europe and the World.
  • High debut sales of new weight loss drugs.
  • Manufacturing challenges due to high demand.
  • Potential changes in U.S. insurance coverage for weight loss medications.

If you have any questions please contact us here. You can also email the author, Joao Guerreiro at jguerreiro@prescouter.com or Jeremy Schmerer at jschmerer@prescouter.com.

Never miss an insight

Get insights delivered right to your inbox

More of Our Insights & Work

Never miss an insight

Get insights delivered right to your inbox

You have successfully subscribed to our newsletter.

Too many subscribe attempts for this email address.